Form 4: Phathom Pharmaceuticals Director James Topper Receives Equity Compensation Package

James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc., was granted 10,500 Restricted Stock Units and options to purchase 17,500 shares of common stock as part of his non-employee director compensation.

Summary

• James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc. (PHAT), received equity compensation on June 3, 2025.
• The compensation includes a grant of 10,500 Restricted Stock Units (RSUs) at a price of $0 per unit.
• These RSUs will vest 100% on the first anniversary of the grant date or the next annual meeting of stockholders, whichever occurs first, contingent on Mr. Topper's continued service on the Board.
• Additionally, Mr. Topper was granted options to purchase 17,500 shares of common stock with an exercise price of $4.95 per share.
• These stock options will also vest on the first anniversary of the grant date or the next annual meeting of stockholders, whichever occurs first, subject to his continued service.
• The options have an expiration date of June 2, 2035.
• Following these transactions, Mr. Topper directly beneficially owns 42,596 shares of common stock.
• Indirect beneficial ownership includes 59,403 shares via Frazier Life Sciences X, L.P., 5,827,415 shares via Frazier Life Sciences IX, L.P., 1 share via FHMLS IX, L.L.C., and 3,912 shares via Topper Group III LLC.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a standard compensation event for a director, aligning their interests with shareholders. It does not contain any negative news or significant operational updates.

Positives

• The grants align the interests of Director James N. Topper with those of shareholders, as his compensation is tied to the company's stock performance.
• The equity compensation is part of the Issuer's Non-Employee Director Compensation Program, indicating a structured approach to rewarding board service.

Risks

• The value of the granted RSUs and stock options is subject to the future market price fluctuations of Phathom Pharmaceuticals' common stock.
• The vesting of both the RSUs and stock options is contingent upon Mr. Topper's continued service on the Board, posing a risk if his service were to cease prematurely.

Future Outlook

The grants of RSUs and stock options, with vesting contingent on continued service, imply an expectation of James N. Topper's ongoing commitment and contribution to the company's Board of Directors.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to attract and retain experienced board members.

Corporate Governance

Stakeholder Impact

• Shareholders: The issuance of new equity (upon RSU vesting and option exercise) could lead to minor dilution, but the grants are intended to align director interests with shareholder value creation.
• Director (James N. Topper): Receives equity-based compensation, which ties his personal financial interest directly to the company's stock performance.

Next Steps

• Vesting of 10,500 Restricted Stock Units on the first anniversary of June 3, 2025, or the next annual meeting of stockholders, subject to continued service.
• Vesting of options to purchase 17,500 shares on the first anniversary of June 3, 2025, or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

SEC Form 4, insider transaction, equity compensation, Restricted Stock Units, RSU, stock options, director compensation, Phathom Pharmaceuticals, PHAT, beneficial ownership